🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

An interim analysis of a phase 1/2 trial shows that a new mRNA influenza and SARS-CoV-2 combination #vaccine is safe and triggers an encouraging immune response. nature.com/articles/s4159…

A cell therapy for celiac disease based on regulatory T cells shows promise in mice and prevents effector T cells from migrating to the gut, hinting cell therapies could one day induce gluten tolerance in the immune system. Science Translational Medicine 📄: scim.ag/4kLLIke

News: Combination therapy shrank a variety of metastatic solid tumors bit.ly/3E1tACl

Mount Sinai researchers, led by Mount Sinai Fuster Heart Hospital's Dr. Robert Rosenson, have found that the RNA-based therapy zodasiran significantly reduces multiple harmful cholesterol and lipid levels in individuals with mixed hyperlipidemia, a major risk factor for heart disease. Published

MD Anderson researchers recently identified an eight-protein blood signature to help predict outcomes for patients with acute myeloid leukemia. One protein stood out as a key predictor of survival and early treatment risk. Learn more: brnw.ch/21wRT0h #EndCancer

Turning all cancers into curable diseases takes urgency, bold ideas and relentless drive. To advance that mission, we’re proud to share that Ira Mellman, PhD, has joined PICI as President of Research. A leader in cancer immunology, Dr. Mellman helped shape therapies like

Researchers Memorial Sloan Kettering Cancer Center have revealed how structures of immune cell clusters, which promote antitumor immunity, form in #PancreaticCancer. Read about the NCI-funded study and how leveraging this mechanism could enable #immunotherapy. go.nih.gov/l1riz78

Presented at #AACR25: Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi  AACR

Early results in patients who had failed prior CAR T: → 81% overall response → 52% complete remission at 3 months → 3-day manufacturing turnaround This research from Carl June and team represents the first IL-18–secreting CAR T tested in blood cancer — and it may reshape

New in Nature Cancer: Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial rdcu.be/eln4d Matt Galsky Bhardwaj Lab Icahn School of Medicine at Mount Sinai

Proulx, Wiggins, Lauffenburger, Sassetti et al. show that noncanonical T cell responses are associated with protection from #tuberculosis in mice and humans hubs.la/Q03kH41K0 📘 In our Clinical #Immunology Collection: hubs.la/Q03kHdBG0 #FOCIS2025

Can personalized vaccines make immunotherapy more effective in bladder cancer? In a new Nature Cancer study, PICI investigator Nina Bhardwaj, MD, PhD, tested PGV001 + atezolizumab. All patients showed immune responses. 3 of 4 in the adjuvant group remained recurrence-free at 39

An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and reduces shedding of the virus in vaccinated volunteers, according to results from a new phase 2 trial. scim.ag/4jWcwxc Vaxart

Brief Report: Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease nej.md/42XF03F Editorial: Progress in the Development of N-of-1 Therapy nej.md/3EUA1rr Science behind the Study: Personalized Gene Editing to Treat an Inborn Error of

New research in Science establishes #CRISPR-associated transposase (CAST) as a powerful platform technology for efficient, RNA-guided gene integration in human cells. scim.ag/3FgKo93

Cancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acceptable treatment options. Read the Clinical Practice article “Cancer of Unknown

Online Now: The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets dlvr.it/TL3d9s

As presented at #ASCO25: Intracerebroventricular infusion of bivalent EGFR and IL13Rα2-targeting #CARTcells in patients with recurrent #glioblastoma was well tolerated with 1 patient with a partial response and 1 patient with durable stable disease nature.com/articles/s4159…

A clinical trial using engineered CAR-T cells to hunt cancer cells has reported impressive results for solid tumours go.nature.com/3SRNOCx

B cell-depletion mitigates MS symptoms but its effects on other immune cells was unclear David A. Hafler Yoshiaki Yasumizu & team now show anti-CD20 therapy affects the amount and function of cerebral spinal fluid macrophages and circulating monocytes: jci.org/articles/view/…